Q-omics provides the consensus-scored ZBTB44 profile across patient tissues and cancer cell-line models. ZBTB44 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZBTB44 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZBTB44 RNA expression shows 21,107 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where ZBTB44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB44 survival associations across molecular data types. ZBTB44 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB44 RNA expression–survival associations across cancer types. High ZBTB44 expression shows unfavorable associations in ACC, but favorable associations in KIRC, UCS, HNSC, READ and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZBTB44 RNA expression.
This table summarizes ZBTB44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB44 shows lower tumor expression in KICH, THCA, BRCA and KIRC and higher tumor expression in LIHC and STAD. The KICH box plot shows higher ZBTB44 RNA expression in normal versus tumor tissue (log2 FC = −0.954, t-test p < 0.001).
This table shows molecular features associated with ZBTB44 in patient tissues and cancer cell lines. In patient samples, ZBTB44 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB44 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
